Details
Stereochemistry | RACEMIC |
Molecular Formula | C18H31NO4 |
Molecular Weight | 325.443 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1
InChI
InChIKey=VHYCDWMUTMEGQY-UHFFFAOYSA-N
InChI=1S/C18H31NO4/c1-14(2)19-11-17(20)13-23-18-7-5-16(6-8-18)12-21-9-10-22-15(3)4/h5-8,14-15,17,19-20H,9-13H2,1-4H3
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.healthline.com/drugs/bisoprolol/oral-tablet#Highlights1
https://www.drugs.com/ppa/bisoprolol.html
http://pharm-sci.tbzmed.ac.ir/Drug-Information/Integrative%20Medicine%20Professional%20Access/ProfDrugs/Bisoprololpd.html
http://www.drugbank.ca/drugs/DB00612
https://en.wikipedia.org/wiki/Bisoprolol
Curator's Comment: description was created based on several sources, including:
http://www.healthline.com/drugs/bisoprolol/oral-tablet#Highlights1
https://www.drugs.com/ppa/bisoprolol.html
http://pharm-sci.tbzmed.ac.ir/Drug-Information/Integrative%20Medicine%20Professional%20Access/ProfDrugs/Bisoprololpd.html
http://www.drugbank.ca/drugs/DB00612
https://en.wikipedia.org/wiki/Bisoprolol
Bisoprolol is a cardioselective beta1-adrenergic blocking agent. It lower the heart rate and blood pressure and may be used to reduce workload on the heart and hence oxygen demands. This results in a reduction of heart rate, cardiac output, systolic and diastolic blood pressure, and possibly reflex orthostatic hypotension. Bisoprolol can be used to treat cardiovascular diseases such as hypertension, coronary heart disease, arrhythmias, ischemic heart diseases, and myocardial infarction after the acute event. General side effects are: fatigue, asthenia, chest pain, malaise, edema, weight gain, angioedema. Concurrent use of rifampin increases the metabolic clearance of bisoprolol fumarate, shortening its elimination half-life.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL213 |
8.8 nM [IC50] | ||
Target ID: CHEMBL289 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9523980 |
|||
Target ID: CHEMBL340 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9523980 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ZIAC Approved UseBISOPROLOL FUMARATE is indicated in the management of hypertension. It may be used alone or in combination with other antihypertensive agents. Launch Date7.330176E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
52 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2887325/ |
10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BISOPROLOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
40.37 ng/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
BISOPROLOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
661 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2887325/ |
10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BISOPROLOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
609.8 ng × h/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
BISOPROLOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2887325/ |
10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BISOPROLOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
11.07 h |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
BISOPROLOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
70% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2887325/ |
10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BISOPROLOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
70% |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
BISOPROLOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
10 mg single, oral |
unhealthy, 37 - 52 years n = 15 Health Status: unhealthy Condition: liver disease Age Group: 37 - 52 years Sex: M+F Population Size: 15 Sources: |
Other AEs: Dizziness, Tiredness... Other AEs: Dizziness (2 patients) Sources: Tiredness (1 patient) Shortness of breath (1 patient) Faintness (1 patient) |
10 mg 1 times / day steady, oral (max) Highest studied dose Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: |
unhealthy, adult n = 1327 Health Status: unhealthy Condition: heart failure Age Group: adult Sex: unknown Population Size: 1327 Sources: |
|
5 mg 1 times / day steady, intravenous (max) Highest studied dose Dose: 5 mg, 1 times / day Route: intravenous Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy, adult n = 37 Health Status: unhealthy Condition: myocardial infarction Age Group: adult Sex: unknown Population Size: 37 Sources: |
|
20 mg 1 times / day steady, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: |
unhealthy, adult n = 273 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 273 Sources: |
Other AEs: Sweating increased, Arthralgia... Other AEs: Sweating increased (0.7%) Sources: Arthralgia (2.2%) Dizziness (2.9%) Headache (8.8%) Hypoaesthesia (1.1%) Dry mouth (0.7%) Bradycardia (0.4%) Insomnia (1.5%) Diarrhea (2.6%) Nausea (1.5%) Vomiting (1.1%) |
20 mg 1 times / day steady, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: |
unhealthy, adult n = 273 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 273 Sources: |
Disc. AE: Bradycardia, Fatigue... AEs leading to discontinuation/dose reduction: Bradycardia (< 1%) Sources: Fatigue (< 1%) |
40 mg 1 times / day steady, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: |
unhealthy, adult n = 404 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 404 Sources: |
Other AEs: Headache, Hypoaesthesia... Other AEs: Headache (10.9%) Sources: Hypoaesthesia (1.5%) Sweating increased (1%) Arthralgia (2.7%) Dizziness (3.5%) Dry mouth (1.3%) Bradycardia (0.5%) Insomnia (2.5%) Depression (0.2%) Diarrhea (3.5%) Nausea (2.2%) Vomiting (1.5%) |
40 mg 1 times / day steady, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: |
unhealthy, adult n = 404 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 404 Sources: |
Disc. AE: Bradycardia, Fatigue... AEs leading to discontinuation/dose reduction: Bradycardia (< 1%) Sources: Fatigue (< 1%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Faintness | 1 patient | 10 mg single, oral |
unhealthy, 37 - 52 years n = 15 Health Status: unhealthy Condition: liver disease Age Group: 37 - 52 years Sex: M+F Population Size: 15 Sources: |
Shortness of breath | 1 patient | 10 mg single, oral |
unhealthy, 37 - 52 years n = 15 Health Status: unhealthy Condition: liver disease Age Group: 37 - 52 years Sex: M+F Population Size: 15 Sources: |
Tiredness | 1 patient | 10 mg single, oral |
unhealthy, 37 - 52 years n = 15 Health Status: unhealthy Condition: liver disease Age Group: 37 - 52 years Sex: M+F Population Size: 15 Sources: |
Dizziness | 2 patients | 10 mg single, oral |
unhealthy, 37 - 52 years n = 15 Health Status: unhealthy Condition: liver disease Age Group: 37 - 52 years Sex: M+F Population Size: 15 Sources: |
Bradycardia | 0.4% | 20 mg 1 times / day steady, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: |
unhealthy, adult n = 273 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 273 Sources: |
Dry mouth | 0.7% | 20 mg 1 times / day steady, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: |
unhealthy, adult n = 273 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 273 Sources: |
Sweating increased | 0.7% | 20 mg 1 times / day steady, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: |
unhealthy, adult n = 273 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 273 Sources: |
Hypoaesthesia | 1.1% | 20 mg 1 times / day steady, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: |
unhealthy, adult n = 273 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 273 Sources: |
Vomiting | 1.1% | 20 mg 1 times / day steady, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: |
unhealthy, adult n = 273 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 273 Sources: |
Insomnia | 1.5% | 20 mg 1 times / day steady, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: |
unhealthy, adult n = 273 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 273 Sources: |
Nausea | 1.5% | 20 mg 1 times / day steady, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: |
unhealthy, adult n = 273 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 273 Sources: |
Arthralgia | 2.2% | 20 mg 1 times / day steady, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: |
unhealthy, adult n = 273 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 273 Sources: |
Diarrhea | 2.6% | 20 mg 1 times / day steady, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: |
unhealthy, adult n = 273 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 273 Sources: |
Dizziness | 2.9% | 20 mg 1 times / day steady, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: |
unhealthy, adult n = 273 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 273 Sources: |
Headache | 8.8% | 20 mg 1 times / day steady, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: |
unhealthy, adult n = 273 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 273 Sources: |
Bradycardia | < 1% Disc. AE |
20 mg 1 times / day steady, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: |
unhealthy, adult n = 273 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 273 Sources: |
Fatigue | < 1% Disc. AE |
20 mg 1 times / day steady, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: |
unhealthy, adult n = 273 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 273 Sources: |
Depression | 0.2% | 40 mg 1 times / day steady, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: |
unhealthy, adult n = 404 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 404 Sources: |
Bradycardia | 0.5% | 40 mg 1 times / day steady, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: |
unhealthy, adult n = 404 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 404 Sources: |
Sweating increased | 1% | 40 mg 1 times / day steady, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: |
unhealthy, adult n = 404 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 404 Sources: |
Dry mouth | 1.3% | 40 mg 1 times / day steady, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: |
unhealthy, adult n = 404 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 404 Sources: |
Hypoaesthesia | 1.5% | 40 mg 1 times / day steady, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: |
unhealthy, adult n = 404 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 404 Sources: |
Vomiting | 1.5% | 40 mg 1 times / day steady, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: |
unhealthy, adult n = 404 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 404 Sources: |
Headache | 10.9% | 40 mg 1 times / day steady, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: |
unhealthy, adult n = 404 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 404 Sources: |
Nausea | 2.2% | 40 mg 1 times / day steady, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: |
unhealthy, adult n = 404 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 404 Sources: |
Insomnia | 2.5% | 40 mg 1 times / day steady, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: |
unhealthy, adult n = 404 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 404 Sources: |
Arthralgia | 2.7% | 40 mg 1 times / day steady, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: |
unhealthy, adult n = 404 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 404 Sources: |
Diarrhea | 3.5% | 40 mg 1 times / day steady, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: |
unhealthy, adult n = 404 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 404 Sources: |
Dizziness | 3.5% | 40 mg 1 times / day steady, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: |
unhealthy, adult n = 404 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 404 Sources: |
Bradycardia | < 1% Disc. AE |
40 mg 1 times / day steady, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: |
unhealthy, adult n = 404 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 404 Sources: |
Fatigue | < 1% Disc. AE |
40 mg 1 times / day steady, oral (max) Recommended Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: |
unhealthy, adult n = 404 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: unknown Population Size: 404 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
[Treatment of cardiac insufficiency: does treatment depend on whether its cause is ischemic or idiopathic?]. | 1999 Jun |
|
Prevention of experimental autoimmune cardiomyopathy in rabbits by receptor blockers. | 2001 |
|
Cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in Sweden: analysis using data from the Cardiac Insufficiency Bisoprolol Study II trial. | 2001 |
|
[Clinical trials on heart failure]. | 2001 |
|
Quantitative structure-retention and retention-activity relationships of beta-blocking agents by micellar liquid chromatography. | 2001 Apr 6 |
|
Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. | 2001 Aug |
|
Predictors of medical events and of their competitive interactions in the Cardiac Insufficiency Bisoprolol Study 2 (CIBIS-2). | 2001 Dec |
|
Immunofluorescent imaging of beta 1- and beta 2-adrenergic receptors in rat kidney. | 2001 Feb |
|
[A must in symptomatic heart failure. Added beta blocker improves prognosis]. | 2001 Feb 1 |
|
[Bisprolol in heart failure: efficacy and costs in a French setting according to CIBIS II]. | 2001 Jul-Aug |
|
Beta-blockers to reduce mortality in patients with systolic dysfunction: a meta-analysis. | 2001 Jun |
|
[Hypertensive diabetic patients. Plus points for selective beta 1-blockade]. | 2001 Jun 7 |
|
Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. | 2001 Mar 13 |
|
Autoimmunity against the second extracellular loop of beta(1)-adrenergic receptors induces beta-adrenergic receptor desensitization and myocardial hypertrophy in vivo. | 2001 Mar 30 |
|
The effects of bisoprolol, a selective beta1-blocker, on glucose metabolism by long-term administration in essential hypertension. | 2001 May |
|
Carvedilol in the treatment of chronic heart failure. | 2001 May |
|
Economic impact of beta blockade in heart failure. | 2001 May 7 |
|
Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension. | 2001 Sep |
|
[Role of beta-blockers in the treatment of chronic heart heart failure]. | 2001 Sep 16 |
|
Bisoprolol: a review of its use in chronic heart failure. | 2002 |
|
Optimising the use of beta-blockers in older patients with heart failure. | 2002 |
|
[The effect of aspirin on rheological properties of erythrocytes in essential hypertension]. | 2002 |
|
Differential effects of bucindolol and carvedilol on noradenaline-induced hypertrophic response in ventricular cardiomyocytes of adult rats. | 2002 Apr |
|
Beta-blockers work as well in women as in men. | 2002 Apr 5 |
|
[Hormonal hyperactivity in heart failure. Differences in beta blockers]. | 2002 Aug |
|
Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies--CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study. | 2002 Feb |
|
Can beta blockers be safely initiated at home in patients with heart failure? | 2002 Jan |
|
Comparison of the affinity of beta-blockers for two states of the beta 1-adrenoceptor in ferret ventricular myocardium. | 2002 Jan |
|
[Therapy relevant differences in beta blockers and ACE inhibitors. Innovation or plagiarism?]. | 2002 Jan 17 |
|
Present and future pharmacotherapy for heart failure. | 2002 Jul |
|
[Heart failure. Only every fifth patient is properly treated?]. | 2002 Jun 20 |
|
Beta-blocker decreases the increase in QT dispersion and transmural dispersion of repolarization induced by bepridil. | 2002 Nov |
|
Functional beta1- and beta2-adrenoceptors in the left and right atrium of pre-hypertensive rats. | 2002 Oct |
|
[Beta blockers in heart failure. Start with low and slowly increase the dosage!]. | 2002 Sep 19 |
|
Storms of ventricular tachyarrhythmias associated with primary hyperparathyroidism in a patient with dilated cardiomyopathy. | 2003 Jan |
Patents
Sample Use Guides
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QC07BB07
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
||
|
NCI_THESAURUS |
C29576
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
12.4
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
||
|
LIVERTOX |
NBK548471
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
||
|
WHO-ATC |
C09BX02
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
||
|
NDF-RT |
N0000175556
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
12.1
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
12.3
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
||
|
WHO-VATC |
QC07AB57
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
||
|
WHO-ATC |
C07FB07
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
||
|
WHO-ATC |
C07FX04
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
||
|
NDF-RT |
N0000000161
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
||
|
WHO-ATC |
C07BB07
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
||
|
WHO-VATC |
QC07AB07
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
||
|
WHO-ATC |
C07AB07
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
||
|
WHO-ATC |
C07AB57
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
||
|
WHO-VATC |
QC07FB07
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
12.2
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000092277
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
PRIMARY | |||
|
SUB13096MIG
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
PRIMARY | |||
|
Y41JS2NL6U
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
PRIMARY | |||
|
Y41JS2NL6U
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
PRIMARY | |||
|
3127
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
PRIMARY | |||
|
Y-69
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
PRIMARY | |||
|
BISOPROLOL
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
PRIMARY | |||
|
19484
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
PRIMARY | RxNorm | ||
|
D017298
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
PRIMARY | |||
|
66722-44-9
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
PRIMARY | |||
|
Bisoprolol
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
PRIMARY | |||
|
2405
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
PRIMARY | |||
|
DB00612
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
PRIMARY | |||
|
5225
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
PRIMARY | |||
|
8316
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
PRIMARY | |||
|
7129
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
PRIMARY | |||
|
DTXSID6022682
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
PRIMARY | |||
|
M2565
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
PRIMARY | Merck Index | ||
|
C61653
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
PRIMARY | |||
|
CHEMBL645
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
PRIMARY | |||
|
380
Created by
admin on Thu Jul 06 02:10:12 UTC 2023 , Edited by admin on Thu Jul 06 02:10:12 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)